New evidence shows that patients with Long COVID syndrome continue to have higher measures of blood clotting, which may help explain their persistent symptoms, such as reduced physical fitness and fatigue. The study, led by researchers from RCSI University of Medicine and Health Sciences, is published in Opens in the Journal of Thrombosis and Haemostasis.
The researchers examined 50 patients with symptoms of Long COVID syndrome to better understand if abnormal blood clotting is involved.
They discovered that clotting markers were significantly elevated in the blood of patients with Long COVID syndrome compared with healthy controls. These clotting markers were higher in patients who required hospitalisation with their initial COVID-19 infection, but they also found that even those who were able to manage their illness at home still had persistently high clotting markers.
FT: “the vaccines send the DNA gene sequences of the spike protein into the cell … Once inside the cell nucleus, certain parts of the spike protein splice, or split apart“
During the last months many countries have started the immunization of millions of people by using vector-based vaccines. Unfortunately, severe side effects became overt during these vaccination campaigns: cerebral venous sinus thromboses (CVST), absolutely rare under normal life conditions, were found as a severe side effect that occured 4-14 days after first vaccinations. Besides CVST, Splanchnic Vein Thrombosis (SVT) was also observed. This type of adverse event has not been observed in the clinical studies of AstraZeneca, and therefore led immediately to a halt in vaccinations in several european countries.
These events were mostly associated with thrombocytopenia, and thus, similar to the well-known Heparin-induced thrombocytopenia (HIT). Meanwhile, scientists have proposed a mechanism to explain this vaccine-induced thrombocytopenia. However, they do not provide a satisfactory explanation for the late thromboembolic events. Here, we present data that may explain these severe side effects which have been attributed to adenoviral vaccines.
According to our results, transcription of wildtype and codon-optimized Spike open reading frames enables alternative splice events that lead to C-terminal truncated, soluble Spike protein variants. These soluble Spike variants may initiate severe side effects when binding to ACE2-expressing endothelial cells in blood vessels. In analogy to the thromboembolic events caused by Spike protein encoded by the SARS-CoV-2 virus, we termed the underlying disease mechanism the “Vaccine-Induced Covid-19 Mimicry” syndrome (VIC19M syndrome).
Researchgate paper “Vaccine-Induced Covid-19 Mimicry Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines”.
FT Article “Scientists claim to have solved Covid vaccine blood-clot puzzle”
Princess Michael of Kent is being treated for blood clots after receiving two doses of the Oxford/AstraZeneca vaccine – although no link has been established. Sources close to the 76-year-old said concerns for her health emerged after she received her second jab earlier this year. The royal has been recovering at home for almost a month.
‘The Princess has been unwell and has sought medical attention,’ a source told the Sun on Sunday. ‘It has been a worrying time for those around her. It has been difficult for those close to her to see her suffering. She’s really been through it.’
The AstraZeneca vaccine has come under scrutiny in Europe after being linked to a very small number of blood clot cases. A scientific review by UK medical regulator MHRA concluded in April that evidence of a link between the vaccine and rare blood clots ‘is stronger but more work is still needed’.
The Spanish Health Department is investigating the death of a corporal, aged 35, assigned to the Infantry Regiment América 66 de Cazadores de Montaña, based in the Aizoáin barracks, Navarra, after suffering a “cerebral sinus thrombosis with thrombocytopenia and cerebral hemorrhage”, 17 days after receiving the AstraZeneca vaccine. The military man died this morning at the University Clinic of Navarra.
The corporal, married and expecting a child, was vaccinated with AstraZeneca on the afternoon of April 7 in his own unit. The Spanish Troop and Sailor Association (ATME) explained that in the following days he suffered “severe headaches and acute discomfort”, which forced him to go to the barracks first aid service and then to the emergency room of a health center from Pamplona. On the night of this last Wednesday, April 21, the corporal suffered a faint while he was at his home, according to the Army, to which America 66 belongs.
Update: “This Friday, the Pharmacovigilance Center of the Health Department of the Government of Navarra has received a notification of a “adverse event with fatal outcome” of a person who had been vaccinated with Vaxzevria (AstraZeneca) on April 7 against Covid-19. Despite the fact that the Provincial Government has reported that he had died after suffering a “cerebral sinus thrombosis with thrombocytopenia and cerebral hemorrhage”, the affected person has not died and is in a situation of brain death.”
The Australian Therapeutic Goods Administration is investigating three new cases of a rare blood clot syndrome “likely” linked to the AstraZeneca vaccine. The cases are a 35-year-old woman, a 49-year-old man and an 80-year-old man. It is the first time the syndrome has been reported in a person over 50 in Australia. The TGA said in a statement all cases were likely linked to the AstraZeneca vaccine. The TGA said one patient developed symptoms “unusually late” – 26 days after the vaccination.
The risk of a serious blood clot from AstraZeneca jab has doubled in a fortnight, new data show. Cases have gone up from 79 to 168 and deaths from 19 to 32. The chance of having a clot following vaccination has gone from one in 250,000 to one in 126,582.
Nine new cases of atypical thrombosis (clots) and two cases of coagulation disorders associated with AstraZeneca’s Covid-19 vaccine, with four additional deaths, occurred in France between April 2 and April 8, according to French health authorities. The nine new cases of rare thrombosis concern people who present “a profile different from that” of the cases declared previously, notes the ANSM. The age of the patients is “higher”: “It is about four women and five men, older (average age of 62 years) who presented more digestive thromboses.
Marie-Antoinette Sevestre-Pietri, French Society of Vascular Medicine President: “”In the long term, it will probably be necessary to do without adenovirus vaccines”
Australian Federal health authorities are investigating the death of a 48-year-old New South Wales woman who developed blood clots after receiving a COVID-19 vaccine. If it is confirmed the woman contracted blood clots linked to a COVID-19 vaccine, it would be the third such case in Australia since the rollout began.
“We are dealing with a whole new syndrome, called WHITE. We have identified that there is an increased risk in using the vaccine. It gives us a figure on the increased risk with the serious disease cases. About 1 in 40,000 of those vaccinated with AstraZeneca’s vaccine are affected and many die,” says Søren Brostrøm.
“We know a lot more today than we did a month ago. We know that there is a possible biological explanation why AstraZeneca’s vaccine may cause these cases. This suggests a cross-reaction. We know that there is a temporal connection – we see cases 8-10 days after the vaccination, «says Søren Brostrøm, who gradually feels on safe scientific grounds when he now puts into words the Danish decision to stop using the vaccine.
A 26-year-old woman on April 13 was in fact hospitalized in a reserved prognosis at the Milan Polyclinic, after vaccination against Covid with AstraZeneca vaccine.
According to what is learned, the twenty-six year old is hospitalized at the Milan Polyclinic with cerebral thrombosis . The girl, according to the hospital, “is conscious and responds to therapies . She is in conditions considered stable, even if the prognosis remains confidential and is kept under close observation”. The hospitalization at the Milan Polyclinic was necessary because her situation was serious, also for this reason the patient was sent to the Thrombosis Center led by Flora Peyvandi, reference structure.
Canada announced on Tuesday its first report of a rare blood clot in a person who had received the AstraZeneca COVID-19 vaccine. The Public Health Agency of Canada (PHAC) and the Quebec health ministry said the female patient, whose age was not revealed, is recovering at home.
“Reports of blood clots with low platelets in people vaccinated with the AstraZeneca COVID-19 vaccine are very rare and the report of this case shows that Canada’s vaccine safety monitoring system works,” PHAC said in a statement.
The second case of rare blood clots linked to the AstraZeneca COVID-19 vaccine has been detected in a woman vaccinated in Western Australia. The Therapeutic Goods Administration said the woman in her 40s is in hospital in a stable condition, receiving treatment.
“The Vaccine Safety Investigation Group (VSIG), a panel of expert advisers to the Therapeutic Goods Administration (TGA) met yesterday evening and has concluded that a recently reported case of thrombosis with thrombocytopenia is likely to be linked to vaccination,” the TGA said in a safety alert.
This is the second Australian case of “thrombosis with thrombocytopenia following the AstraZeneca COVID-19 vaccine”.
The Food and Drug Administration (FDA) said six cases in 6.8 million doses had been reported and it was acting “out of an abundance of caution”. Johnson & Johnson said it was also delaying vaccine rollout in Europe. The US move follows similar rare cases in the AstraZeneca vaccine, which has prompted some curbs in its use.
“As of April 2, 2021, 42 cases of a central venous / sinus vein thrombosis reported after vaccination with Vaxzevria. In 23 Thrombocytopenia has also been reported in cases.
In one case where post mortem a central sinus vein thrombosis with cerebral hemorrhage was found, the platelet count could no longer be reliably determined. With the exception of seven cases, they affected all others. Cases in women aged 20 to 63 years. The men were 24 to 58 Year old. Eight patients (5 women, 3 men) died.
For some of the patients who have had post-vaccination sinus thrombosis with thrombocytopenia, high platelet antibodies were found which are common with the clinical picture of a disease similar to an autoimmune one Heparin-induced thrombocytopenia (aHIT). And a HIT Thromboses can also occur without the administration of heparin.
The Paul Ehrlich Institute has numerically more case reports from Sinus vein thrombosis after vaccination with Vaxzevria in women before (83.3% vs. 16.7%), whereby young women were particularly often affected. However, according to the information provided by Robert Koch Institute, women were also vaccinated more often than men. There were significantly more cases for women aged 20-59 years observed than expected based on the background incidence.”
Report download (PDF): Suspected side effects and vaccination complications after vaccination to protect against COVID-19 (Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19)